Consensus Guidelines and Recommendations for the anti-CD38-based Therapy in Clinical Practice for Relapsed/Refractory Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working Group

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Expert consensus outlines treatment strategies and considerations for anti-CD38 therapy in RRMM, highlighting efficacy in high-risk patients.

Anti-CD38-based regimens achieve durable responses in elderly patients, requiring careful monitoring and support.
Regimen selection and patient stratification are crucial for optimizing treatment of relapsed/refractory multiple myeloma.
Strategies for managing hematologic toxicities are essential to improve patient outcomes in this population.
Rechallenge with anti-CD38 mAbs can be feasible after a washout period, restoring immune function in high-risk cases.

Chen et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Expert consensus outlines treatment strategies and considerations for anti-CD38 therapy in RRMM, highlighting efficacy in high-risk patients.